Lilly, Resilience to Invest $750M in Ohio Manufacturing

Editor’s Take: Lilly has made several high-profile investments in the U.S. in the past year. In January, it chose the Lehigh Valley in Pennsylvania for its next manufacturing site, and in May, the company announced an additional $4.5 billion investment across two of its Indiana sites.

Resilience and Eli Lilly and Company will invest $750 million to expand Resilience’s advanced manufacturing operations in the Cincinnati, Ohio region, adding production of Lilly’s KwikPen injectable device for diabetes and obesity medicines.

According to the partners, the addition of KwikPen production will create at least 400 new high-skilled jobs, bringing total Resilience-created jobs in Ohio to more than 1,400 across its facilities. Site preparation for the campus expansion is underway, with full operations expected to commence in early 2027.

“We are proud of what we have built together with Lilly and this new expansion as we scale production of complex medicines in Ohio,” said William S. Marth, President and CEO of Resilience. “Our investment reflects our long-term commitment to building one of the largest and most advanced sterile injectable and device assembly and packaging operations in the United States, and demonstrates how trusted partnerships, operational excellence, and disciplined execution can strengthen America’s medicine supply.”

Edgardo Hernandez, Lilly’s EVP and President, Manufacturing Operations, added, “As demand for our medicines continues to increase, scaling complex manufacturing programs requires proven technical capability, an uncompromising commitment to quality, and the ability to deliver consistently over time. Today’s announcement highlights Resilience’s role as a strong partner to Lilly in strengthening domestic supply of high-demand treatments.”

The multi-year manufacturing partnership between Lilly and Resilience has already produced more than 150 million doses of medicines for patients in the United States in vial and pre-filled syringe formats. Together, the companies have established one of the nation’s largest sterile injectable manufacturing operations.